About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT06116110

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

Lead sponsor: Miltenyi Biomedicine GmbH•5 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Contacts

Sadie Swift

CONTACT

617-218-0044 clinicaltrials@miltenyi.com

Paris Jamiel

CONTACT

617-218-0044 clinicaltrials@miltenyi.com

Sponsors

Lead Sponsor

Miltenyi Biomedicine GmbH

This is a non-therapeutic study design. After successful screening, subjects will be monitored for potential gene therapy-related adverse events for up to 15 years post MB-CART2019.1 infusion. Subjects will be assessed yearly for the occurrence of delayed adverse events (AEs), monitored for replication competent lentivirus (RCL) and assessed for long term efficacy as well as CAR-T persistence.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Received zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study and have either completed the study or have discontinued early from the study.
•Provided written informed consent to participate in this study.

Exclusion Criteria

•None

Related studies

Familial Investigations of Childhood Cancer Predisposition

NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more

Pre-malignant States to Hematologic Malignancies in Firefighters

NCT06870760 · Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy, and more

RECRUITINGPhase 2

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069 · Mantle Cell Lymphoma, Non Hodgkin Lymphoma, and more

RECRUITINGPhase 2

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

NCT07125872 · Relapsed B-Cell Non Hodgkin Lymphoma

RECRUITINGPhase 1/2

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

NCT05442515 · B-NHL, B-Non Hodgkin Lymphoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 20, 2024Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment150

Start dateMay 2024

Last updatedNov 20, 2024

Condition

Non Hodgkin Lymphoma

Locations shown

Stanford University

Stanford, California

Yale University

New Haven, Connecticut

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

Baltimore, Maryland

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 20, 2024Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions